SNOA (Mkap $22 M) Cash $12.6 M) Etliche Produkte am Markt + weitere Produkteinführungen (Seite 18)
eröffnet am 11.08.17 14:10:41 von
neuester Beitrag 10.06.23 11:37:12 von
neuester Beitrag 10.06.23 11:37:12 von
Beiträge: 176
ID: 1.259.169
ID: 1.259.169
Aufrufe heute: 0
Gesamt: 31.212
Gesamt: 31.212
Aktive User: 0
ISIN: US83558L2043 · WKN: A2PMPH · Symbol: O8Z3
0,1402
EUR
-1,13 %
-0,0016 EUR
Letzter Kurs 08.05.24 Tradegate
Neuigkeiten
09.04.24 · Accesswire  |
04.04.24 · Accesswire |
28.03.24 · Accesswire |
27.03.24 · Accesswire |
13.11.23 · Accesswire |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7400 | +36,63 | |
| 4,6400 | +27,82 | |
| 3,5100 | +27,64 | |
| 57,50 | +20,29 | |
| 0,6510 | +18,88 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,6250 | -17,12 | |
| 2,0500 | -28,32 | |
| 0,9380 | -30,00 | |
| 2,5900 | -32,11 | |
| 2,4100 | -51,51 |
Beitrag zu dieser Diskussion schreiben
Feedback
Vorletzte Woche hat SNOA eine weitere FDA Zulassung erhalten die aber wegen der konkurrenz wohl nicht öffentlicht gemacht wurde auch gibt es keine nähere details zum dem Produkt . Es werden u.a noch einige Zulassungen in Südamerika für dieses Jahr erwartet und eventuell auch in Asien und Markteinführung von Loyon in USA ist für Oktober geplant .Man sieht diese kleine Firma hat so einiges im Angebot und auch die Zahlen bewegen sich in die richtige Richtung jetzt bleibt nur noch abzuwarten wie schnell sie die Profitabilität erreichen die sie für 2018 angepeilt haben .
Auch Management hat den Absturz genutzt um ein paar Aktien zu kaufen ist nicht viel bisher aber trotzdem
http://openinsider.com/search?q=snoa
With $19.5 Million in Coffers from Asset Sale, Sonoma Pharmaceuticals Sets Sights on Breakeven -- SECFilings.com
https://finance.yahoo.com/news/19-5-million-coffers-asset-14…
Transkript
https://seekingalpha.com/article/4098556-sonoma-pharmaceutic…
Dermatology prescriptions filled for the first quarter were up 66% over last year and up 24% even versus the March 2017 quarter.
Our growing sales team now totals 30 sales reps and 5 managers. All reps have been trained, are out in the field generating prescriptions, and we are pleased to see the team hitting new weekly sales records for prescriptions filled at the pharmacy counter almost every week.
From a clinical trial perspective, we saw a publication of two studies, describing the benefits of Celacyn, our prescription scar management product, and for Sebuderm for the treatment of facial and scalp seborrheic dermatitis. Both studies are available online, in print and are great tools for our growing sales force when speaking with our customers, the dermatologists.
Our profit center businesses, which we define as our international business, acute care, animal health and our contract lab testing, are all on track for profitable growth for our full fiscal year.
And finally, our cash is healthy and we have almost no debt.
As Bob and I discuss often, it's a great time to be running this growing company with a dedicated team, all pushing towards the same goals and objectives.
Switching gears, a brief look ahead. Loyon, our skin descaling product, licensed from a German pharma company, was recently approved by the FDA and is on track for a launch in October.
You may have seen, we just received our 17th FDA approval last week for a new product and a new indication. For competitive reasons, we're not in a position to discuss this product or the timing for the launch. But suffice it to say that we should have an active nine months ahead with the FDA.
In Brazil, the regulatory equivalent of the FDA, which is Anvisa, asked us for more information on our pending dermatology products in the June timeframe. We've already answered their questions and provided all requested information.
We now expect up to seven new dermatology product approvals – and I'm going to repeat that, not launches, but approvals – specifically for the Brazilian dermatology market this fall.
As you'll no doubt remember, Brazil has become the world's third-largest market for beauty products after the US and Japan. And in plastic surgery and in dermatology procedures, Brazil is now the world's second-biggest market after the US.
Additionally, we have a handful of new approvals pending in the Middle East and in China. And we look forward to providing you with more information on our international dermatology growth soon.
So, in closing, we had a strong quarter due to our team's focus on our execution. We are well positioned for the remainder of this year and beyond.
Auch Management hat den Absturz genutzt um ein paar Aktien zu kaufen ist nicht viel bisher aber trotzdem
http://openinsider.com/search?q=snoa
With $19.5 Million in Coffers from Asset Sale, Sonoma Pharmaceuticals Sets Sights on Breakeven -- SECFilings.com
https://finance.yahoo.com/news/19-5-million-coffers-asset-14…
Transkript
https://seekingalpha.com/article/4098556-sonoma-pharmaceutic…
Dermatology prescriptions filled for the first quarter were up 66% over last year and up 24% even versus the March 2017 quarter.
Our growing sales team now totals 30 sales reps and 5 managers. All reps have been trained, are out in the field generating prescriptions, and we are pleased to see the team hitting new weekly sales records for prescriptions filled at the pharmacy counter almost every week.
From a clinical trial perspective, we saw a publication of two studies, describing the benefits of Celacyn, our prescription scar management product, and for Sebuderm for the treatment of facial and scalp seborrheic dermatitis. Both studies are available online, in print and are great tools for our growing sales force when speaking with our customers, the dermatologists.
Our profit center businesses, which we define as our international business, acute care, animal health and our contract lab testing, are all on track for profitable growth for our full fiscal year.
And finally, our cash is healthy and we have almost no debt.
As Bob and I discuss often, it's a great time to be running this growing company with a dedicated team, all pushing towards the same goals and objectives.
Switching gears, a brief look ahead. Loyon, our skin descaling product, licensed from a German pharma company, was recently approved by the FDA and is on track for a launch in October.
You may have seen, we just received our 17th FDA approval last week for a new product and a new indication. For competitive reasons, we're not in a position to discuss this product or the timing for the launch. But suffice it to say that we should have an active nine months ahead with the FDA.
In Brazil, the regulatory equivalent of the FDA, which is Anvisa, asked us for more information on our pending dermatology products in the June timeframe. We've already answered their questions and provided all requested information.
We now expect up to seven new dermatology product approvals – and I'm going to repeat that, not launches, but approvals – specifically for the Brazilian dermatology market this fall.
As you'll no doubt remember, Brazil has become the world's third-largest market for beauty products after the US and Japan. And in plastic surgery and in dermatology procedures, Brazil is now the world's second-biggest market after the US.
Additionally, we have a handful of new approvals pending in the Middle East and in China. And we look forward to providing you with more information on our international dermatology growth soon.
So, in closing, we had a strong quarter due to our team's focus on our execution. We are well positioned for the remainder of this year and beyond.
Antwort auf Beitrag Nr.: 55.509.129 von Geri78 am 11.08.17 19:40:26Ja verlust war etwas höher als letztes Jahr weil weiteres Personal beim Verkaufsteam eingestellt worden ist aber der Absturz lag hauptsächlich an dem gestrigen schlechten Marktumfeld da sind solche low floater sehr volatil . Und das momentan noch kein interesse da ist liegt daran das die Aktie nicht viele kennen was sehr gut für Neueinsteiger ist sonst würde sie mit sicherheit weit höher notieren .
Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018
https://finance.yahoo.com/news/sonoma-pharmaceuticals-report…
Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018
https://finance.yahoo.com/news/sonoma-pharmaceuticals-report…
Antwort auf Beitrag Nr.: 55.509.042 von Geri78 am 11.08.17 19:27:46noch wird kein gewinn generiert, der verlust stattdessen höher als im Vorjahr...deswegen die enttäuschung vielleicht
Antwort auf Beitrag Nr.: 55.507.710 von Biohero am 11.08.17 16:49:13klingt interessant.
aber warum der absturz heute ?
und warum so wenig Interesse ?
Vielen Dank
lG
aber warum der absturz heute ?
und warum so wenig Interesse ?
Vielen Dank
lG
Antwort auf Beitrag Nr.: 55.506.327 von Biohero am 11.08.17 14:10:41Es sind wirklich sehr erfahrene Leute hier tätig wie oben auch in der Präsentation zu lesen ist .SNOA ist eine der ganz wenigen Firmen die sich sogar als Langfristinvestment eignet das Potential ist enorm wenn sie das so in die tat umsetzen wie angegeben .So eine Firma an der Nasdaq mit so vielen Produkten am Markt für diese Bewertung wird man wohl kein zweites mal finden .
Speziell dieses Produkt das in kürze in USA verkauft wird hat gutes Marktpotential
Sonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon® Skin Descaler for Relief of Scaling Associated with Various Dermatoses...
http://www.baystreet.ca/quotedata/news-article.aspx
Market Size
It is estimated that 25% of the general population has some degree of scaling associated with skin dermatoses. “Although the diagnosis is often overlooked and undervalued, the treatment of the symptoms is just as integral as slowing the process,” said Neal Bhatia, MD., director of clinical dermatology, Therapeutics Clinical Research. “The presentation may be more aggressive in patients with HIV, neurologic disorders, infants and the elderly. More importantly, options for symptom control are limited and dermatologists are in need of new options.”
Speziell dieses Produkt das in kürze in USA verkauft wird hat gutes Marktpotential
Sonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon® Skin Descaler for Relief of Scaling Associated with Various Dermatoses...
http://www.baystreet.ca/quotedata/news-article.aspx
Market Size
It is estimated that 25% of the general population has some degree of scaling associated with skin dermatoses. “Although the diagnosis is often overlooked and undervalued, the treatment of the symptoms is just as integral as slowing the process,” said Neal Bhatia, MD., director of clinical dermatology, Therapeutics Clinical Research. “The presentation may be more aggressive in patients with HIV, neurologic disorders, infants and the elderly. More importantly, options for symptom control are limited and dermatologists are in need of new options.”
Trading Spotlight
Was soll ich schreiben man braucht sich nur die Fundamentaldaten anschauen die sprechen schon für sich , Marktkap liegt bei $22 Million über die hälfte davon als Cash ($12.6 Million) vorhanden haben etliche Produkte am Markt für kernbereich Hautkrankheiten Jahresumsatz steuert auf die $16 Million zu weitere Produkteinführungen sind innerhalb der nächsten 6-7 monate geplant und natürlich die extrem niedrige Aktienanzahl von nur 4.3 Million . Ein Nasdaq-Wert das so niedrig bewertet ist ,gut finanziert ist ,schon ordentlich Umsatz macht und natürlich so wenig Aktien im Umlauf hat ist schon eine echte rarität . Das bereits vorhande Cash soll ausreichen um den breakeven zu erreichen laut Management .
In den letzten 2 Tagen wurde die Aktie hauptsächlich wegen dem schlechten Marktumfeld mit in die tiefe gerrissen was mMn eine gute Einstiegschance bietet , ich zumindest hab eine kleine Position bei $5.20 aufgebaut kleine position deshalb weil ich erstmal abwarten will was am Gesamtmarkt geschieht und solche low floater extrem volatil sind obwohl das Abwärtspotential eher gering ist .
Bei $50 pro Aktie würde die Marktkap rund $215 Million betragen das ist nicht viel und auch machbar hängt aber natürlich vom Gesamtmarkt ab das ist jetzt entscheidend wie es da weitergeht .
Regulatory Approvals and Clearances
To date, we have obtained 17 clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States.
Outside the United Sates, we sell products for dermatological and advanced tissue care with a European Conformity marking (known as Conformité Européenne or CE) covering 25 of our products, and various approvals in Central America, China, Southeast Asia, and the Middle East.
Sonoma Pharma (Nasdaq: SNOA)
Marktkap: 22.1 Million
Cash: $12.6 Million
Kurs: $5.15
Aktienanzahl : 4.3 Million
Präsentation Juni
http://ir.sonomapharma.com/common/download/download.cfm?comp…
Fact Sheet
http://files.shareholder.com/downloads/OCLS/4977255852x0x231…
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures
•Celacyn for scar treatment
•Mondoxyne for severe acne –launched late 2015
•Ceramax for skin repair in atopic dermatitis–launched in April 2016
•SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017
•Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
In den letzten 2 Tagen wurde die Aktie hauptsächlich wegen dem schlechten Marktumfeld mit in die tiefe gerrissen was mMn eine gute Einstiegschance bietet , ich zumindest hab eine kleine Position bei $5.20 aufgebaut kleine position deshalb weil ich erstmal abwarten will was am Gesamtmarkt geschieht und solche low floater extrem volatil sind obwohl das Abwärtspotential eher gering ist .
Bei $50 pro Aktie würde die Marktkap rund $215 Million betragen das ist nicht viel und auch machbar hängt aber natürlich vom Gesamtmarkt ab das ist jetzt entscheidend wie es da weitergeht .
Regulatory Approvals and Clearances
To date, we have obtained 17 clearances from the U.S. Food and Drug Administration, or FDA, that permit us to sell our products as medical devices for Section 510(k) of the Federal Food, Drug and Cosmetic Act in the United States.
Outside the United Sates, we sell products for dermatological and advanced tissue care with a European Conformity marking (known as Conformité Européenne or CE) covering 25 of our products, and various approvals in Central America, China, Southeast Asia, and the Middle East.
Sonoma Pharma (Nasdaq: SNOA)
Marktkap: 22.1 Million
Cash: $12.6 Million
Kurs: $5.15
Aktienanzahl : 4.3 Million
Präsentation Juni
http://ir.sonomapharma.com/common/download/download.cfm?comp…
Fact Sheet
http://files.shareholder.com/downloads/OCLS/4977255852x0x231…
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures
•Celacyn for scar treatment
•Mondoxyne for severe acne –launched late 2015
•Ceramax for skin repair in atopic dermatitis–launched in April 2016
•SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017
•Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
Durchsuchen
